MX2023014274A - Compuestos indol sustituidos y metodos de uso de los mismos. - Google Patents
Compuestos indol sustituidos y metodos de uso de los mismos.Info
- Publication number
- MX2023014274A MX2023014274A MX2023014274A MX2023014274A MX2023014274A MX 2023014274 A MX2023014274 A MX 2023014274A MX 2023014274 A MX2023014274 A MX 2023014274A MX 2023014274 A MX2023014274 A MX 2023014274A MX 2023014274 A MX2023014274 A MX 2023014274A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods
- substituted indol
- complement
- indol compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163196339P | 2021-06-03 | 2021-06-03 | |
| US202163290019P | 2021-12-15 | 2021-12-15 | |
| US202263346120P | 2022-05-26 | 2022-05-26 | |
| PCT/US2022/032042 WO2022256586A2 (en) | 2021-06-03 | 2022-06-03 | Substituted indole compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014274A true MX2023014274A (es) | 2024-04-22 |
Family
ID=84323595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014274A MX2023014274A (es) | 2021-06-03 | 2022-06-03 | Compuestos indol sustituidos y metodos de uso de los mismos. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20240287034A1 (OSRAM) |
| EP (1) | EP4346812A4 (OSRAM) |
| JP (1) | JP2024521878A (OSRAM) |
| KR (1) | KR20240017004A (OSRAM) |
| CN (1) | CN120081822A (OSRAM) |
| AU (1) | AU2022283903A1 (OSRAM) |
| BR (1) | BR112023025235A2 (OSRAM) |
| CA (1) | CA3222144A1 (OSRAM) |
| CL (1) | CL2023003591A1 (OSRAM) |
| CO (1) | CO2023016557A2 (OSRAM) |
| CR (1) | CR20230564A (OSRAM) |
| DO (1) | DOP2023000263A (OSRAM) |
| EC (1) | ECSP23090260A (OSRAM) |
| IL (1) | IL308835A (OSRAM) |
| JO (1) | JOP20230315A1 (OSRAM) |
| MX (1) | MX2023014274A (OSRAM) |
| PE (1) | PE20250114A1 (OSRAM) |
| PH (1) | PH12023553130A1 (OSRAM) |
| WO (1) | WO2022256586A2 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230286947A1 (en) * | 2020-08-07 | 2023-09-14 | Shanghai Meiyue Biotech Development Co. Ltd | Complement factor b inhibitor, and pharmaceutical composition, preparation method and use thereof |
| JP7641388B2 (ja) * | 2020-12-30 | 2025-03-06 | エス－インフィニティ ファーマシューティカルズ カンパニー リミテッド | 一連のピペリジン置換安息香酸系化合物及びその使用 |
| EP4362933A4 (en) * | 2021-06-30 | 2025-06-04 | Apellis Pharmaceuticals, Inc. | COMPLEMENT INHIBITION |
| CA3229360A1 (en) | 2021-08-18 | 2023-02-23 | Chen Zhang | Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine |
| EP4423076A4 (en) * | 2021-10-27 | 2026-01-07 | Hansoh Bio Llc | PIPERIDINYL INDOLE DERIVATIVES, THEIR PREPARATION PROCESSES AND MEDICAL USES |
| CR20240300A (es) * | 2022-01-24 | 2024-08-23 | Novartis Ag | Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos. |
| CN119301114A (zh) * | 2022-06-07 | 2025-01-10 | 正大天晴药业集团股份有限公司 | 双环取代的芳香羧酸类氘代化合物 |
| WO2023246677A1 (zh) * | 2022-06-20 | 2023-12-28 | 深圳信立泰药业股份有限公司 | 一种吲哚-苯基哌啶化合物及其制备方法与应用 |
| CN119546585A (zh) * | 2022-06-23 | 2025-02-28 | 上海济煜医药科技有限公司 | 吲哚化合物的制备、应用及用途 |
| WO2024049977A1 (en) * | 2022-08-31 | 2024-03-07 | Chinook Therapeutics, Inc. | Substituted indole compounds and methods of use thereof |
| JP2025530222A (ja) * | 2022-09-10 | 2025-09-11 | 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 | ２－置換ピペリジン誘導体、その製造方法及び医薬的用途 |
| KR20250107882A (ko) * | 2022-11-14 | 2025-07-14 | 노파르티스 파르마 아게 | 보체 인자 b 억제제의 고체 형태 |
| TWI869080B (zh) * | 2022-11-29 | 2025-01-01 | 大陸商上海濟煜醫藥科技有限公司 | 苯並螺環吲哚化合物的製備及用途 |
| WO2024148274A1 (en) * | 2023-01-05 | 2024-07-11 | Apellis Pharmaceuticals, Inc. | Complement inhibition |
| EP4650351A1 (en) * | 2023-01-09 | 2025-11-19 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Inhibitor of complement factor b |
| AU2024221845A1 (en) * | 2023-02-16 | 2025-09-11 | Haisco Pharmaceutical Group Co., Ltd. | Salt of benzo-nitrogen heteroaromatic ring derivative, crystalline form, and pharmaceutical use thereof |
| EP4670719A1 (en) * | 2023-02-22 | 2025-12-31 | Haisco Pharmaceutical Group Co., Ltd. | PHARMACEUTICAL COMPOSITION OF A HETEROAROMATIC BENZO-NITROGEN RING DERIVATIVE AND ITS USE IN MEDICINE |
| WO2024222852A1 (zh) * | 2023-04-27 | 2024-10-31 | 上海翰森生物医药科技有限公司 | 一种哌啶基吲哚化合物的盐及其制备方法 |
| WO2025008451A1 (en) | 2023-07-04 | 2025-01-09 | Sitala Bio Ltd | 2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors |
| AU2024290587A1 (en) | 2023-07-04 | 2026-02-19 | Sitala Bio Ltd | 2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors |
| EP4739667A2 (en) | 2023-07-06 | 2026-05-13 | Sitala Bio Ltd | Indole derivatives with factor b inhibitory activity |
| WO2025008517A1 (en) | 2023-07-06 | 2025-01-09 | Sitala Bio Ltd | Indole derivatives with factor b inhibitory activity |
| TWI896250B (zh) * | 2023-07-26 | 2025-09-01 | 大陸商上海美悦生物科技發展有限公司 | 螺環烯基類或氮雜烯基類化合物及其藥物組合物、製備方法和用途 |
| TW202517258A (zh) * | 2023-09-20 | 2025-05-01 | 大陸商上海美悦生物科技發展有限公司 | 雜環化合物在製備預防和／或治療腎臟疾病的藥物中的用途 |
| TW202535375A (zh) * | 2023-12-05 | 2025-09-16 | 大陸商西藏海思科製藥有限公司 | 苯並氮雜芳環衍生物在治療補體因數b介導的疾病中的用途 |
| WO2025172535A1 (en) | 2024-02-15 | 2025-08-21 | Sitala Bio Ltd | Indole and benzimidazole compounds as factor b inhibitors |
| WO2025256647A1 (zh) * | 2024-06-14 | 2025-12-18 | 润尔眼科药物（广州）有限公司 | 化合物及其医药用途 |
| WO2026008073A1 (zh) * | 2024-07-05 | 2026-01-08 | 南京正大天晴制药有限公司 | 补体因子b抑制剂的剂量组合物 |
| WO2026069246A1 (en) * | 2024-09-30 | 2026-04-02 | Novartis Ag | Complement factor b inhibitors and uses thereof |
| CN121949280A (zh) * | 2024-10-31 | 2026-05-01 | 甫康（上海）健康科技有限责任公司 | 一种多取代吲哚类化合物及其制备方法和用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6180514B2 (ja) * | 2012-05-04 | 2017-08-16 | ノバルティス アーゲー | 補体経路モジュレーターおよびその使用 |
| EP2867225B1 (en) * | 2012-06-28 | 2017-08-09 | Novartis AG | Pyrrolidine derivatives and their use as complement pathway modulators |
| JO3425B1 (ar) * | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| CN109414441A (zh) * | 2016-06-27 | 2019-03-01 | 艾其林医药公司 | 治疗医学障碍的喹唑啉和吲哚化合物 |
| US20230286947A1 (en) | 2020-08-07 | 2023-09-14 | Shanghai Meiyue Biotech Development Co. Ltd | Complement factor b inhibitor, and pharmaceutical composition, preparation method and use thereof |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| CR20230614A (es) | 2021-06-03 | 2024-02-01 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos médicos |
| US20240294517A1 (en) | 2021-06-24 | 2024-09-05 | Syngenta Crop Protection Ag | 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides |
| CA3224494A1 (en) | 2021-07-09 | 2023-01-12 | Koen Vandyck | Anti-viral compounds |
| CA3226387A1 (en) | 2021-07-26 | 2023-02-02 | Joel D. Moore | Rock2 inhibitors and uses thereof |
| EP4423076A4 (en) * | 2021-10-27 | 2026-01-07 | Hansoh Bio Llc | PIPERIDINYL INDOLE DERIVATIVES, THEIR PREPARATION PROCESSES AND MEDICAL USES |
| AR127922A1 (es) | 2021-12-15 | 2024-03-13 | Syngenta Crop Protection Ag | Derivados heterocíclicos bicíclicos microbiocidas |
| US20250326757A1 (en) | 2022-05-26 | 2025-10-23 | Astrazeneca Ab | Solid forms of heterocyclylamides as irak4 inhibitors |
-
2022
- 2022-06-03 MX MX2023014274A patent/MX2023014274A/es unknown
- 2022-06-03 JP JP2023574119A patent/JP2024521878A/ja active Pending
- 2022-06-03 BR BR112023025235A patent/BR112023025235A2/pt unknown
- 2022-06-03 PE PE2023003178A patent/PE20250114A1/es unknown
- 2022-06-03 CR CR20230564A patent/CR20230564A/es unknown
- 2022-06-03 WO PCT/US2022/032042 patent/WO2022256586A2/en not_active Ceased
- 2022-06-03 IL IL308835A patent/IL308835A/en unknown
- 2022-06-03 KR KR1020237045081A patent/KR20240017004A/ko active Pending
- 2022-06-03 PH PH1/2023/553130A patent/PH12023553130A1/en unknown
- 2022-06-03 CN CN202510248844.6A patent/CN120081822A/zh active Pending
- 2022-06-03 US US18/566,259 patent/US20240287034A1/en active Pending
- 2022-06-03 AU AU2022283903A patent/AU2022283903A1/en active Pending
- 2022-06-03 CA CA3222144A patent/CA3222144A1/en active Pending
- 2022-06-03 EP EP22816892.8A patent/EP4346812A4/en active Pending
-
2023
- 2023-11-30 CL CL2023003591A patent/CL2023003591A1/es unknown
- 2023-11-30 JO JOJO/P/2023/0315A patent/JOP20230315A1/ar unknown
- 2023-11-30 EC ECSENADI202390260A patent/ECSP23090260A/es unknown
- 2023-11-30 CO CONC2023/0016557A patent/CO2023016557A2/es unknown
- 2023-11-30 DO DO2023000263A patent/DOP2023000263A/es unknown
-
2025
- 2025-05-30 US US19/223,498 patent/US12617774B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023025235A2 (pt) | 2024-02-27 |
| DOP2023000263A (es) | 2024-02-29 |
| US12617774B2 (en) | 2026-05-05 |
| CN120081822A (zh) | 2025-06-03 |
| CL2023003591A1 (es) | 2024-06-28 |
| WO2022256586A3 (en) | 2023-01-12 |
| PE20250114A1 (es) | 2025-01-16 |
| EP4346812A2 (en) | 2024-04-10 |
| US20240287034A1 (en) | 2024-08-29 |
| CO2023016557A2 (es) | 2024-02-26 |
| PH12023553130A1 (en) | 2024-03-11 |
| CA3222144A1 (en) | 2022-12-08 |
| AU2022283903A1 (en) | 2023-11-30 |
| CR20230564A (es) | 2024-02-27 |
| US20250289804A1 (en) | 2025-09-18 |
| ECSP23090260A (es) | 2024-02-29 |
| EP4346812A4 (en) | 2025-04-09 |
| KR20240017004A (ko) | 2024-02-06 |
| JOP20230315A1 (ar) | 2023-11-30 |
| WO2022256586A2 (en) | 2022-12-08 |
| IL308835A (en) | 2024-01-01 |
| JP2024521878A (ja) | 2024-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12023553130A1 (en) | Substituted indole compounds and methods of use thereof | |
| CL2024003191A1 (es) | Compuestos de modulación de kras g12d | |
| ECSP22052564A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| CO2022015638A2 (es) | Compuestos, composiciones farmacéuticas y métodos para la preparación de compuestos y para su uso | |
| CO2026004964A2 (es) | Moduladores de kras | |
| ECSP10010004A (es) | Derivados de indol 2-carboxi sustituidos y métodos para su utilización | |
| CO2021005884A2 (es) | Moduladores de la alfa-1 antitripsina | |
| CR11036A (es) | Derivados y composiciones de isoindol 4' -o- sustituidos, composiciones que las comprenden y metodos de uso de los mismos | |
| AR062875A1 (es) | Compuestos de n- metilaminometil isoindol y composiciones que los comprenden y metodos para utilizarlos | |
| CY1125022T1 (el) | Μεθοδοι για θεραπεια καταστασεων που συνδυαζονται με εξαρτωμενη απο masp-2 ενεργοποιηση συμπληρωματος | |
| ECSP099378A (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| CL2008002538A1 (es) | Compuestos derivados de indol sustituidos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral | |
| EA200970190A1 (ru) | Соединения индола | |
| NI200900040A (es) | Derivados de quinazolinona 5-substituidos como agentes antitumorales. | |
| ECSP099775A (es) | Terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario | |
| ECSP088676A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
| CU24707B1 (es) | Inihibidores del factor d del complemento para administración oral | |
| MX2019009610A (es) | Metodos para aumentar en plasma sanguineo la 2'-desoxiuridina (durd) y la inhibicion de la timidilato sintasa. | |
| DOP2025000055A (es) | Moduladores de la alfa-1 antitripsina | |
| CL2025000581A1 (es) | Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren | |
| CR11584A (es) | Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina | |
| CO2025003888A2 (es) | Nuevos derivados pirazina-carboxamida sustituidos | |
| ES2168240T3 (es) | Uso de inhibidores de aceticolina-esterasa para tratar delirios. | |
| ECSP003321A (es) | Nuevas sulfonamidas heterociclicas |